[{"id":"60175a3a-039d-4fa5-932d-b2536bc3f475","acronym":"","url":"https://clinicaltrials.gov/study/NCT07117305","created_at":"2025-08-16T14:06:42.122Z","updated_at":"2025-08-16T14:06:42.122Z","phase":"Phase 1/2","brief_title":"CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT07117305","lead_sponsor":"Zhengzhou University","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-08-12"},{"id":"4bb42519-747d-45f0-98ad-774255094bb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT07109518","created_at":"2025-08-09T14:25:49.588Z","updated_at":"2025-08-09T14:25:49.588Z","phase":"Phase 1","brief_title":"uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","source_id_and_acronym":"NCT07109518","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/28/2025","start_date":" 06/28/2025","primary_txt":" Primary completion: 06/28/2028","primary_completion_date":" 06/28/2028","study_txt":" Completion: 06/28/2030","study_completion_date":" 06/28/2030","last_update_posted":"2025-08-07"},{"id":"7a9b9cc2-6f03-4498-b926-18b38cfd8aef","acronym":"","url":"https://clinicaltrials.gov/study/NCT07106723","created_at":"2025-08-09T14:48:30.931Z","updated_at":"2025-08-09T14:48:30.931Z","phase":"Phase 2","brief_title":"Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL","source_id_and_acronym":"NCT07106723","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 01/07/2029","primary_completion_date":" 01/07/2029","study_txt":" Completion: 01/07/2030","study_completion_date":" 01/07/2030","last_update_posted":"2025-08-06"},{"id":"7883fa9a-7075-4f79-91ca-579902335b6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07008872","created_at":"2025-06-07T14:17:33.977Z","updated_at":"2025-06-07T14:17:33.977Z","phase":"","brief_title":"CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia","source_id_and_acronym":"NCT07008872","lead_sponsor":"Qi deng","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2025-06-06"},{"id":"0a6aefb7-2166-498d-888e-ed54ef581ee3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792948","created_at":"2021-01-18T03:00:33.783Z","updated_at":"2025-02-25T12:25:29.112Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00792948","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 01/06/2026","study_completion_date":" 01/06/2026","last_update_posted":"2025-02-24"},{"id":"33da474f-b112-4a34-ad2b-bf3aa8c54e06","acronym":"AALL1231","url":"https://clinicaltrials.gov/study/NCT02112916","created_at":"2021-01-18T09:46:35.591Z","updated_at":"2025-02-25T16:51:23.270Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT02112916 - AALL1231","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 847","initiation":"Initiation: 10/04/2014","start_date":" 10/04/2014","primary_txt":" Primary completion: 03/31/2020","primary_completion_date":" 03/31/2020","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-04"},{"id":"a5f14953-ab61-4581-b513-a86ad8a1e2b8","acronym":"AALL0434","url":"https://clinicaltrials.gov/study/NCT00408005","created_at":"2021-01-17T17:29:32.376Z","updated_at":"2025-02-25T16:50:52.092Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT00408005 - AALL0434","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1895","initiation":"Initiation: 01/22/2007","start_date":" 01/22/2007","primary_txt":" Primary completion: 09/30/2017","primary_completion_date":" 09/30/2017","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-04"},{"id":"8ec351f2-1bd5-4f00-9a41-65c5a39f754f","acronym":"HTLP-ONCO","url":"https://clinicaltrials.gov/study/NCT04707300","created_at":"2021-01-19T20:51:47.092Z","updated_at":"2025-02-25T17:00:53.937Z","phase":"Phase 1/2","brief_title":"Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients with Hematologic Malignancies (HTLP-ONCO)","source_id_and_acronym":"NCT04707300 - HTLP-ONCO","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" HLA-DRB1 • CD34 • CD4 • CD7","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation","tags":["HLA-DRB1 • CD34 • CD4 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMART 102"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/16/2022","start_date":" 02/16/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-03"},{"id":"d44cb79f-7272-4177-89dd-61604796cccb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06720324","created_at":"2025-02-25T20:22:40.610Z","updated_at":"2025-02-25T20:22:40.610Z","phase":"Phase 1/2","brief_title":"CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors","source_id_and_acronym":"NCT06720324","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/31/2024","start_date":" 12/31/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-12-06"},{"id":"9f7f9253-08cf-4953-b6cf-4724356c6c74","acronym":"","url":"https://clinicaltrials.gov/study/NCT04938115","created_at":"2021-06-24T16:52:55.621Z","updated_at":"2024-07-02T16:34:25.693Z","phase":"","brief_title":"Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia","source_id_and_acronym":"NCT04938115","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • SENL101"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 05/10/2021","start_date":" 05/10/2021","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2024-06-14"},{"id":"928e30bf-7cde-48fe-9006-0210ef5ddbda","acronym":"","url":"https://clinicaltrials.gov/study/NCT05885464","created_at":"2023-06-02T14:05:57.682Z","updated_at":"2024-07-02T16:34:59.472Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","source_id_and_acronym":"NCT05885464","lead_sponsor":"Beam Therapeutics Inc.","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BEAM-201"],"overall_status":"Recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 05/25/2023","start_date":" 05/25/2023","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-06-03"},{"id":"cab3b137-c452-48a2-a45f-fa993e3403a2","acronym":"CD7-CAR01","url":"https://clinicaltrials.gov/study/NCT06064903","created_at":"2023-10-03T19:11:26.359Z","updated_at":"2024-07-02T16:35:00.577Z","phase":"Phase 1/2","brief_title":"CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL","source_id_and_acronym":"NCT06064903 - CD7-CAR01","lead_sponsor":"Bambino Gesù Hospital and Research Institute","biomarkers":" CD7","pipe":" | ","alterations":" CD7 expression","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 04/21/2024","start_date":" 04/21/2024","primary_txt":" Primary completion: 09/30/2028","primary_completion_date":" 09/30/2028","study_txt":" Completion: 09/30/2040","study_completion_date":" 09/30/2040","last_update_posted":"2024-05-29"},{"id":"3052bc57-4b7f-4d7b-af0a-54caa20088ad","acronym":"BAH244","url":"https://clinicaltrials.gov/study/NCT06420063","created_at":"2024-05-25T04:14:21.722Z","updated_at":"2024-07-02T16:35:01.962Z","phase":"Phase 1/2","brief_title":"Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML","source_id_and_acronym":"NCT06420063 - BAH244","lead_sponsor":"Essen Biotech","biomarkers":" CD5 • CD7","pipe":"","alterations":" ","tags":["CD5 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 10/10/2024","start_date":" 10/10/2024","primary_txt":" Primary completion: 12/10/2025","primary_completion_date":" 12/10/2025","study_txt":" Completion: 12/28/2026","study_completion_date":" 12/28/2026","last_update_posted":"2024-05-22"},{"id":"cb8bf821-dc6c-45cb-b69e-e0395df8d0ca","acronym":"BAH246","url":"https://clinicaltrials.gov/study/NCT06420076","created_at":"2024-05-25T04:25:14.770Z","updated_at":"2024-07-02T16:35:02.887Z","phase":"Phase 1/2","brief_title":"Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells","source_id_and_acronym":"NCT06420076 - BAH246","lead_sponsor":"Essen Biotech","biomarkers":" CD5 • CD7","pipe":"","alterations":" ","tags":["CD5 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/10/2024","start_date":" 09/10/2024","primary_txt":" Primary completion: 12/10/2025","primary_completion_date":" 12/10/2025","study_txt":" Completion: 12/28/2026","study_completion_date":" 12/28/2026","last_update_posted":"2024-05-17"},{"id":"f1ccd897-fa87-4dc4-b81e-968077056ea4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02840747","created_at":"2021-01-18T13:56:38.730Z","updated_at":"2024-07-02T16:35:06.284Z","phase":"","brief_title":"Tissue Repository: CTCL Collection Protocol","source_id_and_acronym":"NCT02840747","lead_sponsor":"Columbia University","biomarkers":" CD8 • CD4 • CD7 • DPP4","pipe":"","alterations":" ","tags":["CD8 • CD4 • CD7 • DPP4"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-02"},{"id":"133062df-44e9-40c7-a190-202d1e3eb4f7","acronym":"CRIMSON-NE","url":"https://clinicaltrials.gov/study/NCT03690011","created_at":"2021-01-18T18:05:13.542Z","updated_at":"2024-07-02T16:35:09.997Z","phase":"Phase 1","brief_title":"Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells","source_id_and_acronym":"NCT03690011 - CRIMSON-NE","lead_sponsor":"Baylor College of Medicine","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2040","study_completion_date":" 05/01/2040","last_update_posted":"2024-04-12"},{"id":"e1b1beee-8596-4e66-9c4b-6af0006c827e","acronym":"RV-CL-PTCL-PI-003974","url":"https://clinicaltrials.gov/study/NCT02232516","created_at":"2021-01-18T10:28:31.078Z","updated_at":"2025-02-25T14:34:54.612Z","phase":"Phase 2","brief_title":"Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT02232516 - RV-CL-PTCL-PI-003974","lead_sponsor":"Northwestern University","biomarkers":" ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5","pipe":" | ","alterations":" ALK negative","tags":["ALK • CD20 • CD8 • TNFRSF8 • PAX5 • CD4 • NCAM1 • CD5 • CXCL13 • GZMB • MME • CD7 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • romidepsin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/11/2015","start_date":" 06/11/2015","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-04-10"},{"id":"e1f4b5d9-cd5a-47dd-995e-7ea37a995e84","acronym":"","url":"https://clinicaltrials.gov/study/NCT05464836","created_at":"2022-07-19T14:54:34.934Z","updated_at":"2024-07-02T16:35:19.865Z","phase":"Phase 2","brief_title":"Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL","source_id_and_acronym":"NCT05464836","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2 • CD8 • CD34 • CD5 • CD7 • CD2","pipe":"","alterations":" ","tags":["BCL2 • CD8 • CD34 • CD5 • CD7 • CD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • limantrafin (CB-103)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/06/2023","start_date":" 04/06/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-02-12"},{"id":"7a9cd977-e974-4fff-b14e-53d075776c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04599556","created_at":"2021-01-19T20:29:53.326Z","updated_at":"2024-07-02T16:35:26.894Z","phase":"Phase 1","brief_title":"Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy","source_id_and_acronym":"NCT04599556","lead_sponsor":"Zhejiang University","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-CD7 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-12-06"},{"id":"8052cf1b-322c-438e-98d9-eb557f6e5514","acronym":"","url":"https://clinicaltrials.gov/study/NCT05290155","created_at":"2022-03-22T13:52:52.913Z","updated_at":"2024-07-02T16:35:27.989Z","phase":"Phase 1","brief_title":"Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies","source_id_and_acronym":"NCT05290155","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"],"overall_status":"Recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 05/04/2022","start_date":" 05/04/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-11-28"},{"id":"06fab5d5-c5d5-4468-a08d-023b001b63e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05995028","created_at":"2023-08-16T16:08:27.573Z","updated_at":"2024-07-02T16:35:33.722Z","phase":"Phase 1","brief_title":"Universal 4SCAR7U Targeting CD7-positive Malignancies","source_id_and_acronym":"NCT05995028","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR7U"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-12"},{"id":"6874df97-e833-4a9e-bd15-5cc442d40050","acronym":"","url":"https://clinicaltrials.gov/study/NCT05377827","created_at":"2022-05-17T11:53:47.550Z","updated_at":"2024-07-02T16:35:33.726Z","phase":"Phase 1","brief_title":"Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies","source_id_and_acronym":"NCT05377827","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD7","pipe":" | ","alterations":" CD7 expression","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e soficabtagene geleucel (WU CART 007)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-10-12"},{"id":"06a32ccb-2e76-4068-b6c6-069ccedeb90b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05979792","created_at":"2023-08-07T14:09:05.739Z","updated_at":"2024-07-02T16:35:39.618Z","phase":"Phase 1","brief_title":"Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma","source_id_and_acronym":"NCT05979792","lead_sponsor":"Zhao Weili","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTD-402"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-21"},{"id":"b480d7b1-b74a-44f5-b489-6721131f675a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05909527","created_at":"2023-06-18T17:07:54.188Z","updated_at":"2024-07-02T16:35:42.049Z","phase":"Phase 1/2","brief_title":"A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma","source_id_and_acronym":"NCT05909527","lead_sponsor":"Guangzhou Bio-gene Technology Co., Ltd","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 CAR-T"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2023-07-25"}]